middle.news
NeuroScientific Advances StemSmart Tech with Crohn’s Trial and $3.5M Raise
9:27am on Wednesday 23rd of July, 2025 AEST
•
Biotechnology
Read Story
NeuroScientific Advances StemSmart Tech with Crohn’s Trial and $3.5M Raise
9:27am on Wednesday 23rd of July, 2025 AEST
Key Points
Acquisition of Isopogen WA Ltd secures exclusive StemSmart stem cell technology
Phase 2 trial shows encouraging efficacy in refractory Crohn’s disease patients
Special Access Program launched targeting fistulising Crohn’s disease
Positive Phase 1 and compassionate use results in steroid-refractory GVHD
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEUROSCIENTIFIC BIOPHARMACEUTICALS (ASX:NSB)
OPEN ARTICLE